Cargando…

Drug fever and acute inflammation from hypercytokinemia triggered by dipeptidyl peptidase‐4 inhibitor vildagliptin

A 69‐year‐old man started taking the dipeptidyl peptidase‐4 inhibitor, vildagliptin. One week later, C‐reactive protein and plasma immunoglobulin E levels were markedly elevated, and the vildagliptin was stopped. After the patient's laboratory findings were normalized, we decided to restart vil...

Descripción completa

Detalles Bibliográficos
Autores principales: Anno, Takatoshi, Kaneto, Hideaki, Kawasaki, Fumiko, Shigemoto, Ryo, Aoyama, Yumi, Kaku, Kohei, Okimoto, Niro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319481/
https://www.ncbi.nlm.nih.gov/pubmed/29607626
http://dx.doi.org/10.1111/jdi.12847
_version_ 1783385067881496576
author Anno, Takatoshi
Kaneto, Hideaki
Kawasaki, Fumiko
Shigemoto, Ryo
Aoyama, Yumi
Kaku, Kohei
Okimoto, Niro
author_facet Anno, Takatoshi
Kaneto, Hideaki
Kawasaki, Fumiko
Shigemoto, Ryo
Aoyama, Yumi
Kaku, Kohei
Okimoto, Niro
author_sort Anno, Takatoshi
collection PubMed
description A 69‐year‐old man started taking the dipeptidyl peptidase‐4 inhibitor, vildagliptin. One week later, C‐reactive protein and plasma immunoglobulin E levels were markedly elevated, and the vildagliptin was stopped. After the patient's laboratory findings were normalized, we decided to restart vildagliptin with the patient's agreement. The next day, he had a high fever, and C‐reactive protein and procalcitonin levels were elevated. Although we failed to find a focus of infection, we started antibiotics therapy. Two days later, the high fever had improved, and the C‐reactive protein level had decreased. A drug lymphocyte stimulation test showed a positive result for vildagliptin. We examined various kinds of cytokine and infection markers just before and after the treatment with vildagliptin. Finally, we diagnosed the patient with vildagliptin‐induced drug fever, probably based on the increase of various inflammatory cytokine levels and the response to this. Taken together, we should be aware of the possibility of vildagliptin inducing drug fever and/or acute inflammation.
format Online
Article
Text
id pubmed-6319481
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-63194812019-01-08 Drug fever and acute inflammation from hypercytokinemia triggered by dipeptidyl peptidase‐4 inhibitor vildagliptin Anno, Takatoshi Kaneto, Hideaki Kawasaki, Fumiko Shigemoto, Ryo Aoyama, Yumi Kaku, Kohei Okimoto, Niro J Diabetes Investig Articles A 69‐year‐old man started taking the dipeptidyl peptidase‐4 inhibitor, vildagliptin. One week later, C‐reactive protein and plasma immunoglobulin E levels were markedly elevated, and the vildagliptin was stopped. After the patient's laboratory findings were normalized, we decided to restart vildagliptin with the patient's agreement. The next day, he had a high fever, and C‐reactive protein and procalcitonin levels were elevated. Although we failed to find a focus of infection, we started antibiotics therapy. Two days later, the high fever had improved, and the C‐reactive protein level had decreased. A drug lymphocyte stimulation test showed a positive result for vildagliptin. We examined various kinds of cytokine and infection markers just before and after the treatment with vildagliptin. Finally, we diagnosed the patient with vildagliptin‐induced drug fever, probably based on the increase of various inflammatory cytokine levels and the response to this. Taken together, we should be aware of the possibility of vildagliptin inducing drug fever and/or acute inflammation. John Wiley and Sons Inc. 2018-05-02 2019-01 /pmc/articles/PMC6319481/ /pubmed/29607626 http://dx.doi.org/10.1111/jdi.12847 Text en © 2018 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Articles
Anno, Takatoshi
Kaneto, Hideaki
Kawasaki, Fumiko
Shigemoto, Ryo
Aoyama, Yumi
Kaku, Kohei
Okimoto, Niro
Drug fever and acute inflammation from hypercytokinemia triggered by dipeptidyl peptidase‐4 inhibitor vildagliptin
title Drug fever and acute inflammation from hypercytokinemia triggered by dipeptidyl peptidase‐4 inhibitor vildagliptin
title_full Drug fever and acute inflammation from hypercytokinemia triggered by dipeptidyl peptidase‐4 inhibitor vildagliptin
title_fullStr Drug fever and acute inflammation from hypercytokinemia triggered by dipeptidyl peptidase‐4 inhibitor vildagliptin
title_full_unstemmed Drug fever and acute inflammation from hypercytokinemia triggered by dipeptidyl peptidase‐4 inhibitor vildagliptin
title_short Drug fever and acute inflammation from hypercytokinemia triggered by dipeptidyl peptidase‐4 inhibitor vildagliptin
title_sort drug fever and acute inflammation from hypercytokinemia triggered by dipeptidyl peptidase‐4 inhibitor vildagliptin
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319481/
https://www.ncbi.nlm.nih.gov/pubmed/29607626
http://dx.doi.org/10.1111/jdi.12847
work_keys_str_mv AT annotakatoshi drugfeverandacuteinflammationfromhypercytokinemiatriggeredbydipeptidylpeptidase4inhibitorvildagliptin
AT kanetohideaki drugfeverandacuteinflammationfromhypercytokinemiatriggeredbydipeptidylpeptidase4inhibitorvildagliptin
AT kawasakifumiko drugfeverandacuteinflammationfromhypercytokinemiatriggeredbydipeptidylpeptidase4inhibitorvildagliptin
AT shigemotoryo drugfeverandacuteinflammationfromhypercytokinemiatriggeredbydipeptidylpeptidase4inhibitorvildagliptin
AT aoyamayumi drugfeverandacuteinflammationfromhypercytokinemiatriggeredbydipeptidylpeptidase4inhibitorvildagliptin
AT kakukohei drugfeverandacuteinflammationfromhypercytokinemiatriggeredbydipeptidylpeptidase4inhibitorvildagliptin
AT okimotoniro drugfeverandacuteinflammationfromhypercytokinemiatriggeredbydipeptidylpeptidase4inhibitorvildagliptin